Seeking Alpha

More on GlaxoSmithKline's (GSK) Q2: Net profit slides 16%. The company says it will "likely see...

More on GlaxoSmithKline's (GSK) Q2: Net profit slides 16%. The company says it will "likely see some impact to performance in China as a result of the current investigation" but notes it is "too early to quantify the extent." Management remains cautious on Europe (where pharmaceutical and vaccine sales were flat) as GSK expects "austerity pressures to continue." The company will remain focused on "targeted divestments of non-core assets" and sees core EPS growth of 3-4% for FY13. Shares flat in premarket trading.(PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|